Transgenomic Posts Drop in Q1 Revenue, Widened Losses | GenomeWeb

NEW YORK, May 11 (GenomeWeb News) - Transgenomic today reported a drop in first-quarter earnings, accompanied by widening net losses and reduced R&D spending.

Transgenomic's revenues for the quarter ended March 31, 2004, were $8.6 million, down 9 percent from $9.5 million in the first quarter of 2004. CEO Collin D'Silva said that revenue from sales of bioconsumables during the quarter increased 35 percent year-over-year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.